European vs 2015-World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms

doi:10.5315/wjh.v4.i3.16

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15714)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-20) series, Tables (1-12) series.

Item

Count

PDF

803

WORD

448

HTML

8691

Figures (1-20)

554

Tables (1-12)

269

Sum=10765

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

870

Download

1745

Sum=2615

Publishing Process of This Article

Item

Count

Browse

1191

Download

1143

Sum=2334

Aug 6, 2015 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Hematology

ISSN

2218-6204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hematol. Aug 6, 2015; 4(3): 16-53
Published online Aug 6, 2015. doi: 10.5315/wjh.v4.i3.16

Full Size Figure Download Figure

Figure 10 Charaterization of polycythemia vera study group defined essential thrombocythemia and polycythemia vera by applying the 2006 European Clinical Molecular and Pathological criteria and 2001 World Health Organization bone marrow features; JAK2^V617F mutated normocellular essential thrombocythemia, prodromal polycythemia vera, classical polycythemia vera and myelofibrosis vs JAK2 wild type normocelluar essential thrombocythemia and chronic idiopathic myelofibrosis or Primary megakaryocytic granulocytic myeloproliferation. WHO: World Health Organization; PV: Polycythemia vera; ECMP: European clinical molecular and pathological; MF: Myelofibrosis; ET: Essential thrombocythemia; MPN: Myeloproliferative neoplasm; PMGM: Primary megakaryocytic granulocytic myeloproliferation; PVSG: Polycythemia vera study group; CALR: Calreticulin.

Citation: Michiels JJ, Valster F, Wielenga J, Schelfout K, Raeve HD. European vs 2015-World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms. World J Hematol 2015; 4(3): 16-53
URL: https://www.wjgnet.com/2218-6204/full/v4/i3/16.htm
DOI: https://dx.doi.org/10.5315/wjh.v4.i3.16